Reconsidering the Optimal Timing of PCSK9 Inhibition After Acute Coronary Syndromes in the Post-AMUNDSEN Era
Patients surviving an acute coronary syndrome (ACS) remain at substantial risk of recurrent cardiovascular events, particularly during the first months after the index event. Current European recommendations support immediate oral high intensity lipid lowering therapy, targeting an LDL-C level <55 mg/dL (<1.4 mmol/L) together with a ≥50% reduction from baseline. More recently, the therapeutic approach has shifted towards earlier treatment intensification with ezetimibe during the index hospitalization. Nevertheless, real-world studies such as DA VINCI and SANTORINI continue to show poor LDL-C goal attainment and limited use of combination lipid-lowering therapy.Recent data from the SWEDEHEART registry further suggest that delayed treatment intensification and late achievement of lipid targets may translate into avoidable residual cardiovascular risk. The AMUNDSEN trial has renewed interest in the optimal timing of PCSK9 inhibition after ACS. Very early initiation of evolocumab resulted in markedly higher LDL-C goal attainment at 1 year compared with conventional care which included the possible selective and delayed use of PCSK9 inhibitors, as recommended in the guidelines (82% vs. 40%). In a disctinct objective, the possibility that early pleiotropic (non-LDL) effects of evolocumab could improve short-term clinical outcome was not confirmed at 1-year followup.These findings raise an important question: should the benefit of lipid-lowering therapy be assessed only according to the LDL-C level achieved at a given time point, or should the duration of exposure to lower LDL-C also be considered? Evidence from randomized trials, meta-analyses, and long-term follow-up studies supports the concept that both the magnitude and duration of LDL-C reduction contribute to cardiovascular benefit. This review discusses the implications of AMUNDSEN in the context of contemporary evidence and examines which patients may derive the greatest benefit from upfront PCSK9 inhibition, considering both recurrent clinical risk and the magnitude of LDL-C reduction required to achieve recommended targets.
Authors
- Gilles Montalescot (ORCID: https://orcid.org/0000-0003-0824-6809)
- Johanne Silvain (ORCID: https://orcid.org/0000-0002-1901-2808)
- Mamas A. Mamas (ORCID: https://orcid.org/0000-0001-9241-8890)
- Elad Asher (ORCID: https://orcid.org/0000-0003-3381-605X)
- Giuseppe Andò (ORCID: https://orcid.org/0000-0001-5552-6382)
- Dan Atar (ORCID: https://orcid.org/0000-0003-1513-8793)
- Mathieu Kernéis (ORCID: https://orcid.org/0000-0002-7141-5209)
- Victorien Monguillon (ORCID: https://orcid.org/0009-0004-3387-7092)
- Pierre François Sabouret (ORCID: https://orcid.org/0000-0002-0243-3673)
- Domenico Giamundo
Publication Details
- Journal
- Cardiology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1159/crd/absag039
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00